[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"af7d23ec-b13e-4076-9480-1b329c34d370","acronym":"DelVIN","url":"https://clinicaltrials.gov/study/NCT05717621","created_at":"2023-02-08T17:00:09.181Z","updated_at":"2025-02-25T15:27:53.533Z","phase":"Phase 1","brief_title":"Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)","source_id_and_acronym":"NCT05717621 - DelVIN","lead_sponsor":"ViMREX GmbH","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A overexpression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/17/2025","study_completion_date":" 01/17/2025","last_update_posted":"2025-02-11"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"7460cc37-d435-44b0-a888-a97d57a2e6c3","acronym":"START-001","url":"https://clinicaltrials.gov/study/NCT05592626","created_at":"2022-10-24T13:57:11.728Z","updated_at":"2025-02-25T17:31:39.938Z","phase":"Phase 1/2","brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05592626 - START-001","lead_sponsor":"Marengo Therapeutics, Inc.","biomarkers":" KRAS • TMB • MSI • RAS","pipe":" | ","alterations":" KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type","tags":["KRAS • TMB • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e invikafusp alfa (STAR0602)"],"overall_status":"Recruiting","enrollment":" Enrollment 365","initiation":"Initiation: 01/04/2023","start_date":" 01/04/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-30"},{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"},{"id":"390f3cd2-f31a-4706-82b7-5a2ff1262bf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923934","created_at":"2021-01-17T17:46:27.086Z","updated_at":"2025-02-25T14:36:43.471Z","phase":"Phase 2","brief_title":"A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers","source_id_and_acronym":"NCT02923934","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 08/22/2017","start_date":" 08/22/2017","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-07-24"},{"id":"7f32c6ae-db00-48e3-960e-6cced44274a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05973487","created_at":"2023-08-03T15:09:34.671Z","updated_at":"2024-07-02T16:34:25.733Z","phase":"Phase 1","brief_title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","source_id_and_acronym":"NCT05973487","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A • PRAME • HLA-C","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-06-14"},{"id":"8219a865-ee1b-4147-b478-9542d52eab59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858310","created_at":"2021-01-18T14:01:47.880Z","updated_at":"2024-07-02T16:34:58.731Z","phase":"Phase 1/2","brief_title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","source_id_and_acronym":"NCT02858310","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-05"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"4f044f18-3e23-4009-90ad-d13973fbf09d","acronym":"KEYNOTE-158","url":"https://clinicaltrials.gov/study/NCT02628067","created_at":"2021-01-17T17:22:08.805Z","updated_at":"2024-07-02T16:35:04.350Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","source_id_and_acronym":"NCT02628067 - KEYNOTE-158","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1609","initiation":"Initiation: 12/18/2015","start_date":" 12/18/2015","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2024-05-10"},{"id":"7c21da8e-5d4d-49d2-b559-c9e8b999b515","acronym":"","url":"https://clinicaltrials.gov/study/NCT03987555","created_at":"2021-01-18T19:36:27.910Z","updated_at":"2024-07-02T16:35:06.257Z","phase":"","brief_title":"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","source_id_and_acronym":"NCT03987555","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2019","start_date":" 11/11/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"85654602-8c7a-453d-b201-09765b8fba23","acronym":"STRIVE","url":"https://clinicaltrials.gov/study/NCT06358469","created_at":"2024-04-10T13:41:57.723Z","updated_at":"2024-07-02T16:35:10.364Z","phase":"","brief_title":"STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision","source_id_and_acronym":"NCT06358469 - STRIVE","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 11/30/2031","study_completion_date":" 11/30/2031","last_update_posted":"2024-04-10"},{"id":"e2e18e0d-d872-46fc-9331-6fc0c0e97f5b","acronym":"IMMCO-1","url":"https://clinicaltrials.gov/study/NCT05000294","created_at":"2021-08-11T14:55:29.843Z","updated_at":"2024-07-02T16:35:14.403Z","phase":"Phase 1/2","brief_title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","source_id_and_acronym":"NCT05000294 - IMMCO-1","lead_sponsor":"University of Florida","biomarkers":" HER-2 • TMB • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR negative + HER-2 positive","tags":["HER-2 • TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR negative + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Fotivda (tivozanib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"4447f964-3a9b-4332-91e1-9325a78d63f6","acronym":"MOST-CIRCUIT","url":"https://clinicaltrials.gov/study/NCT04969887","created_at":"2021-07-21T13:52:37.689Z","updated_at":"2025-02-25T14:16:13.555Z","phase":"Phase 2","brief_title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","source_id_and_acronym":"NCT04969887 - MOST-CIRCUIT","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-03-08"},{"id":"55c21f83-a0e4-4e9b-947b-7ac8365bc89c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787535","created_at":"2023-03-28T14:05:07.469Z","updated_at":"2024-07-02T16:35:21.209Z","phase":"Phase 1","brief_title":"HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT05787535","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-02"},{"id":"ef8056a0-9ebe-4f7d-a6ed-854f7c1cbfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952947","created_at":"2023-07-20T14:08:58.725Z","updated_at":"2024-07-02T16:35:21.083Z","phase":"Phase 1","brief_title":"HRYZ-T101 Injection for HPV18 Positive Solid Tumor","source_id_and_acronym":"NCT05952947","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-02-02"},{"id":"2365a87d-8e35-400d-9a3b-2c370f444652","acronym":"20-C-0104","url":"https://clinicaltrials.gov/study/NCT04432597","created_at":"2021-01-29T07:20:51.032Z","updated_at":"2024-07-02T16:35:28.048Z","phase":"Phase 1/2","brief_title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","source_id_and_acronym":"NCT04432597 - 20-C-0104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PRGN-2009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2023-11-27"},{"id":"fab296e5-5776-4c85-9ae1-37929f5d2dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT05686226","created_at":"2023-01-17T14:59:13.286Z","updated_at":"2024-07-02T16:35:33.810Z","phase":"Phase 2","brief_title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","source_id_and_acronym":"NCT05686226","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • E7 TCR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-12"},{"id":"6b12518b-80ef-430a-abf4-75afc134a955","acronym":"LATENT","url":"https://clinicaltrials.gov/study/NCT03357757","created_at":"2021-01-18T16:34:26.903Z","updated_at":"2024-07-02T16:35:33.916Z","phase":"Phase 2","brief_title":"Avelumab With Valproic Acid in Virus-associated Cancer","source_id_and_acronym":"NCT03357757 - LATENT","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HSP90AA1","pipe":" | ","alterations":" TILs","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 02/26/2027","study_completion_date":" 02/26/2027","last_update_posted":"2023-10-11"},{"id":"cd9c68a8-062c-418a-8a7a-3f467abc3209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639972","created_at":"2022-12-07T16:57:48.136Z","updated_at":"2024-07-02T16:35:33.860Z","phase":"Phase 1/2","brief_title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","source_id_and_acronym":"NCT05639972","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • E7 TCR cells • E7 TCR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-11"},{"id":"faedfac2-65dd-4c6b-904b-b67c966013f8","acronym":"POPCORN","url":"https://clinicaltrials.gov/study/NCT06028724","created_at":"2023-09-08T20:10:03.599Z","updated_at":"2024-07-02T16:35:37.399Z","phase":"","brief_title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","source_id_and_acronym":"NCT06028724 - POPCORN","lead_sponsor":"Centro di Riferimento Oncologico - Aviano","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 782","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2023-09-12"}]